Webinar, FAQ Report & Decision Aid | COVID-19 & Neuromuscular Disorders: Ask The Experts
Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) have received numerous questions about COVID-19 vaccines and how they may uniquely affect people with neuromuscular disorders (NMD).
To address these questions and concerns, MDC & NMD4C assembled a diverse group of neuromuscular, virology, and policy experts to host a webinar with the purpose of answering these topical questions.
From this expert-led webinar, the MDC & NMD4C have developed a frequently asked questions report and decision aid tool as resources to summarize the experts’ answers, and to provide guidance for informed patient decision making.
You can access the Frequently Asked Questions Report, Decision Aid, and webinar recording below!
Report: Frequently Asked Questions – COVID-19 & Neuromuscular Disorders
Decision Aid: I have a NMD, should I get a vaccine for COVID-19
We are excited to have the following experts address questions about NMDs, COVID-19 and vaccines:
- Dr. Hans Katzberg, adult neuromuscular specialist and NMD researcher
- Dr. Hanns Lochmuller, pediatric neuromuscular specialist and NMD researcher
- Dr. Reshma Amin, respirologist and NMD researcher
- Dr. Megan Bettle, Director of the COVID-19 Regulatory Response Team at Health Canada / Government of Canada
- Dr. Allison McGeer, Infectious Disease Specialist and COVID-19 researcher
- Dr. Anne Pham-Huy, Infectious Disease Specialist and Chair of Immunize Canada
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.